Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patient suffering from:~* acute leukemia with white blood cell (WBC) count≥ 20,000/mm3 without regard to uric acid level ; or~* lymphoma,Stage ≥ III without regard to uric acid level; or~* lymphomas, Stage II with bulky disease; or~* lymphoma or leukemia, without regard to classification or morphology, with uric acid level ≥ 8.0 mg/dL, and lactate dehydrogenase (LDH) level ≥ twice the upper limit of normal (ULN).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).